- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 807 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 95
- States / cities
- Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 46
- States / cities
- Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 99
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
- Conditions
- Diabetes, Surgery
- Interventions
- Lantus, Insulin
- Drug · Other
- Lead sponsor
- Tamra Dukatz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Royal Oak, Michigan • Troy, Michigan
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Fresno, California
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Complication
- Interventions
- iSage App with connected glucometer, Magnet
- Device · Behavioral
- Lead sponsor
- Amalgam Rx, Inc.
- Industry
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Hyperglycemia, Diabetes
- Interventions
- insulin glargine
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Glulisine (Apidra)
- Drug
- Lead sponsor
- Carl T. Hayden VA Medical Center
- Federal
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more